DIVISLABNSEDivi's Laboratories Limited· PharmaceuticalsHighPositive
Announced Sat, 23 May · 12:15 IST

Divi's Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 23, 2026, recommended Final Dividend of Rs. 30 per equity share.

Exceptional ItemResults View source PDF

DIVISLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.3%1-day move
₹6900.00
prior close
₹6750.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1+1.4+1.1+2.0-2.3-1.6-3.2-5.0-5.7-4.6-2.5-2.9+7.8
Up moveDown movePending
AI summary

Divi's Laboratories reported strong FY 2025-26 results with consolidated total income of ₹11,067 crores, up 13.9% from ₹9,712 crores in the previous year. Consolidated profit after tax grew 17.2% to ₹2,568 crores from ₹2,191 crores. On a standalone basis, revenue from operations was ₹10,388 crores (up 12.9%) and PAT was ₹2,607 crores (up 18%). The Board recommended a final dividend of ₹30 per equity share (1500% on face value of ₹2), subject to shareholder approval at the AGM on August 10, 2026. An exceptional item of ₹74 crores was recognized due to the impact of new Indian Labour Codes, which the company stated is non-recurring. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated financial statements.

Likely market impact

The company delivered solid double-digit growth in both revenue and profit, with a clean audit opinion boosting confidence. The dividend of ₹30 per share signals financial health and cash generation, likely positive for shareholder sentiment.